Palomar Medical Technologies (PMTI)

ITEM 8.01 OTHER EVENTS

       On June 1, 2009, Palomar Medical Technologies, Inc. (the “Company”) received 510(k) Over-The-Counter (OTC) clearance from the United States Food and Drug Administration (FDA) for the first home use wrinkle removal laser device. The Company issued a press release announcing this clearance which is filed as Exhibit 99.1 to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the FDA notification letter which is also filed as Exhibit 99.2 to this Current Report on Form 8-K.

Item 8.01. Other Events.

      On October 7, 2008, we announced the completion of a patent infringement trial brought against us by Candela Corporation in the United States District Court for the Eastern District of Texas. A copy of the press release announcing the decision is set forth as Exhibit 99.1 and is incorporated by reference herein.

ITEM 8.01 OTHER EVENTS

       On December 8, 2006, Palomar Medical Technologies, Inc. (the “Company”) received 510(k) Over-The-Counter (OTC) clearance from the United States Food and Drug Administration (FDA) for the first home use light-based hair removal device. The Company issued a press release announcing this clearance which is filed as Exhibit 99.1 to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the FDA notification letter which is also filed as Exhibit 99.2 to this Current Report on Form 8-K.

ITEM 8.01 OTHER EVENTS

      On October 18, 2006, Palomar Medical Technologies, Inc. (the “Company”), a Delaware corporation, and Laserscope, a California corporation, entered into a Non-Exclusive Patent License Agreement. The Company included an announcement of this agreement in the press release announcing earnings for the third quarter ended September 30, 2006 which is filed as Exhibit 99.1 to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the Non-Exclusive Patent License Agreement which is also filed as Exhibit 99.2 to this Current Report on Form 8-K.

ITEM  8.01   OTHER EVENTS

        On June 2, 2006, Palomar Medical Technologies, Inc., a Delaware corporation (the “Company”), and The General Hospital Corporation, a Massachusetts corporation, settled their patent infringement suits against Cutera, Inc., a Delaware corporation, with the Parties entering into a Settlement Agreement (the “Settlement Agreement”) and with the Company and Cutera, Inc. entering into a Patent License Agreement (the “License Agreement”). The Company’s press release announcing this settlement is entitled “PALOMAR ANNOUNCES SUCCESSFUL CONCLUSION OF PATENT INFRINGEMENT LAWSUITS AGAINST CUTERA Cutera Admits Infringement and Validity of Palomar Patents for Both Laser and Lamp Products” and is filed as Exhibit 99.5 to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the Settlement Agreement and the License Agreement both of which are also filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.

        With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including but not limited to statements relating to new markets, development and introduction of new products, and financial projections that involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2005 and the Company’s quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.